Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines.
A recent working group convened by the World Health Organization recommended that time to first or only episode of clinical malaria should be used to evaluate vaccine efficacy in phase III trials. However, calculating vaccine efficacy based on this endpoint misses important aspects of malaria diseas...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2009
|
| _version_ | 1797076552218836992 |
|---|---|
| author | O'Meara, W Lang, T |
| author_facet | O'Meara, W Lang, T |
| author_sort | O'Meara, W |
| collection | OXFORD |
| description | A recent working group convened by the World Health Organization recommended that time to first or only episode of clinical malaria should be used to evaluate vaccine efficacy in phase III trials. However, calculating vaccine efficacy based on this endpoint misses important aspects of malaria disease and transmission. Here, we discuss the gaps that this approach leaves in predicting the potential public health impact of a vaccine and the challenges faced by vaccine trial designers. We examine the implications of current vaccine trial design on effectiveness studies and the next generation of malaria vaccines. |
| first_indexed | 2024-03-07T00:05:21Z |
| format | Journal article |
| id | oxford-uuid:775b24bd-40cf-4c36-a08c-26406126cc08 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:05:21Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:775b24bd-40cf-4c36-a08c-26406126cc082022-03-26T20:23:27ZMalaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:775b24bd-40cf-4c36-a08c-26406126cc08EnglishSymplectic Elements at Oxford2009O'Meara, WLang, TA recent working group convened by the World Health Organization recommended that time to first or only episode of clinical malaria should be used to evaluate vaccine efficacy in phase III trials. However, calculating vaccine efficacy based on this endpoint misses important aspects of malaria disease and transmission. Here, we discuss the gaps that this approach leaves in predicting the potential public health impact of a vaccine and the challenges faced by vaccine trial designers. We examine the implications of current vaccine trial design on effectiveness studies and the next generation of malaria vaccines. |
| spellingShingle | O'Meara, W Lang, T Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines. |
| title | Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines. |
| title_full | Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines. |
| title_fullStr | Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines. |
| title_full_unstemmed | Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines. |
| title_short | Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines. |
| title_sort | malaria vaccine trial endpoints bridging the gaps between trial design public health and the next generation of vaccines |
| work_keys_str_mv | AT omearaw malariavaccinetrialendpointsbridgingthegapsbetweentrialdesignpublichealthandthenextgenerationofvaccines AT langt malariavaccinetrialendpointsbridgingthegapsbetweentrialdesignpublichealthandthenextgenerationofvaccines |